

The publication arising from this study can be found here:

[Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial | Oncology | JAMA Oncology | JAMA Network](#)

S. Banerjee, G. Giannone, A. Clamp, D. Ennis, R. Glasspool, R. Herbertson, J. Krell, R. Riisnaes, H.B. Mirza, Z. Cheng, J. McDermott, C. Green, R.S. Kristeleit, A. George, C. Gourley, L-A Lewsley, D. Rai¹³, U. Banerji, S. Hinsley, I.A. McNeish

JAMA Oncol. 2023;9(S):675-682

DOI: 10.1001/jamaoncol.2022.7966